CN1216913C - 人白细胞介素-17受体样分子融合蛋白及其编码基因与表达细胞系 - Google Patents
人白细胞介素-17受体样分子融合蛋白及其编码基因与表达细胞系 Download PDFInfo
- Publication number
- CN1216913C CN1216913C CN 02123965 CN02123965A CN1216913C CN 1216913 C CN1216913 C CN 1216913C CN 02123965 CN02123965 CN 02123965 CN 02123965 A CN02123965 A CN 02123965A CN 1216913 C CN1216913 C CN 1216913C
- Authority
- CN
- China
- Prior art keywords
- sequence
- fusion protein
- protein
- leu
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 21
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 title claims abstract description 9
- 102000043448 human IL17RA Human genes 0.000 title claims abstract description 9
- 108020001507 fusion proteins Proteins 0.000 title abstract description 18
- 102000037865 fusion proteins Human genes 0.000 title abstract description 16
- 230000014509 gene expression Effects 0.000 title abstract description 10
- 238000005070 sampling Methods 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 5
- 230000004927 fusion Effects 0.000 claims description 14
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 230000008034 disappearance Effects 0.000 claims description 2
- 230000010473 stable expression Effects 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 abstract description 9
- 108010087819 Fc receptors Proteins 0.000 abstract description 9
- 206010011498 Cryptorchism Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 201000000160 cryptorchidism Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 206010060862 Prostate cancer Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 abstract 1
- 206010057644 Testis cancer Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 208000021267 infertility disease Diseases 0.000 abstract 1
- 201000003120 testicular cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 19
- 238000001890 transfection Methods 0.000 description 12
- 239000006180 TBST buffer Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 102000040739 Secretory proteins Human genes 0.000 description 3
- 108091058545 Secretory proteins Proteins 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 102220023257 rs387907546 Human genes 0.000 description 3
- 102220023256 rs387907547 Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000039989 IL-17 family Human genes 0.000 description 2
- 108091069193 IL-17 family Proteins 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102220023258 rs387907548 Human genes 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 210000002863 seminiferous tubule Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000721 basilar membrane Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 102220369446 c.1274G>A Human genes 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003229 cytophilic effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102220004457 rs11567847 Human genes 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种人白细胞介素-17受体样分子融合蛋白及其编码基因与表达细胞系,本发明所提供的人白细胞介素-17受体样蛋白与可溶性Fc受体的融合蛋白,它具有序列表中序列2的氨基酸残基序列或将序列2的氨基酸残基序列经过一个或几个氨基酸残基的取代、缺失或添加且能够用来寻找IL-17RLM-L的潜在偶联配体的由序列2衍生的蛋白质。本发明的融合蛋白可望在治疗男性生殖不育、隐睾、睾丸癌、前列腺癌及某些炎症性疾病中得到广泛应用。
Description
技术领域
本发明涉及一种融合蛋白及其编码基因,该融合蛋白的表达细胞系与应用;特别是涉及一种人白细胞介素-17受体样分子融合蛋白及其编码基因,该融合蛋白的表达细胞系与应用。
背景技术
白细胞介素是一类重要的细胞因子,可以通过与靶细胞膜表面的特异受体结合而介导广泛的生物学作用,诸如:细胞增殖、分化、造血调节、免疫及炎症应答等。白细胞介素17(IL-17/IL-17A)是IL-17家族第一个被克隆的T细胞来源的促炎症细胞因子。人IL-17通常以一个二硫键连接组成的同二聚体分泌性糖蛋白形式存在,分子质量为30~35kD。尽管IL-17只在局限的组织和细胞系表达,但却有广泛的生物学功能,尤其是在促炎症和造血功能方面较为突出。另外,IL-17还能刺激多种细胞因子的产生,如:来源于巨嗜细胞的肿瘤坏死因子α,来源于成纤维细胞的IL-1β、IL-6、IL-8、ICAM-1以及来源于滑膜细胞的G-CSF、PGE2等。
尽管目前至少已克隆了7种IL-17家族成员,但有关该家族成员的受体研究却知之甚少。本发明的发明人经研究,发现了一种人白细胞介素-17受体样蛋白,并将其命名为hIL-17RLM-L(专利申请号:02123447.7)。该蛋白是一种I型单跨膜细胞因子受体,氮末端含有一个信号肽,一个跨膜结构域和一个较长的胞浆结构域,其较长的胞浆结构域还含有一个潜在的SH3相互作用结构域和众多的酪氨酸磷酸化部位,在胞浆邻膜区含有一个Toll/IL-1受体样结构域-TIR。hIL-17RLM-L基因在肾及睾丸具有较多的表达,少量在心、脑、脾、子宫表达。研究表明,hIL-17RLM-L在生精过程中具有细胞表达特异性,主要在睾丸组织的生精细胞、支持细胞表达,而在曲细精管基底膜部位的成纤维细胞和睾丸支持组织部位的间质细胞染色阴性。在隐睾组织,生精过程中止,但是hIL-17RLM-L在曲细精管的生精细胞却有极强的染色。hIL-17RLM-L可以使Stat5因子活化,同时还具有介导细胞增殖的作用。
可溶性Fc-受体融合蛋白经常被用来体外研究配体与受体之间的相互作用,及特异阻断IL-17RLM的潜在配体所介导的信号通路和生物学效应。为了寻找IL-17RLM-L的潜在偶联配体,构建并表达纯化可溶性Fc受体与hIL-17RLM-L的融合蛋白是一种行之有效的手段。
发明内容
本发明的目的是提供一种人白细胞介素-17受体样蛋白与可溶性Fc受体的融合蛋白及其编码基因。
一种人白细胞介素-17受体样蛋白与可溶性Fc受体的融合蛋白,它具有序列表中序列2的氨基酸残基序列或将序列2的氨基酸残基序列经过一个或几个氨基酸残基的取代、缺失或添加且能够用来寻找IL-17RLM-L的潜在偶联配体的由序列2衍生的蛋白质。
本发明的序列2由531个氨基酸残基组成,编码它的基因是由1620个核苷酸组成的序列表中序列1的DNA序列。
本发明的第二个目的是提供一株能够稳定分泌人白细胞介素-17受体样蛋白与可溶性Fc受体融合蛋白的细胞系。
本发明提供的细胞系为可溶性人白细胞介素-17受体样分子稳定表达细胞系X-931 CGMCC №0755及其突变体或变异体。
细胞系X931,已于2002年06月27日保藏在中国微生物菌种保藏管理委员会普通微生物中心,其简称为CGMCC,保藏编号为CGMCC №0755。
本发明巧妙地将人IgG1.Fc的编码序列克隆于pcDNA3真核表达载体,然后再将人白细胞介素-17受体样蛋白的胞外区亚克隆于pcDNA3-IgG1.Fc真核表达载体的N-末端,并使其编码阅读框一致,转染293T细胞,收集被转染细胞培养上清中的融合蛋白。SDS-PAGE显示所纯化的融合蛋白具有较高的纯度。
本发明的融合蛋白可望在治疗男性生殖不育、隐睾、睾丸癌、前列腺癌及某些炎症性疾病(如类风湿性关节炎等)中得到广泛应用。
具体实施方式
实施例1、稳定分泌人白细胞介素-17受体样蛋白与可溶性Fc受体融合蛋白细胞系的建立
1、转染前一天,传代293T细胞至60mm培养皿(1×105),使细胞在转染时达到40-80%的细胞汇合率(conflucence);
2、在转染时,稀释5μg Fc融合蛋白表达质粒DNA于装有无血清和抗生素的细胞培养基的转染管。瞬时离心几秒钟。添加20μl Superfection转染试剂于DNA溶液,瞬时离心10秒钟;
3、室温(15-25℃)孵育样品5-10分钟,允许转染复合体的形成;
4、在转染复合体形成时,轻柔吸弃培养盘中的培养基,PBS洗涤;
5、添加1000μl细胞生长培养基(含血清和抗生素)于转染复合体,轻柔混匀两次后,小心转移至培养盘中的细胞表面;
6、在正常细胞培养条件下,孵育转染复合体和细胞2-3小时;
7、吸取培养基(含转染复合体),PBS洗涤一次,添加4ml新鲜的细胞生长培养基,培养36-48小时;
8、1∶10或1∶15传代细胞于含有1.2mg/ml G418的选择性培养基的6孔培养盘。每隔3天后,更新选择性培养基,直至15天左右,出现细胞克隆为止。(增强绿色荧光蛋白表达质粒作为转染对照,检测转染效率);
9、扩大培养单克隆细胞至适宜密度。采用Northern blot(也可以用RT-PCR或Western blot)鉴定阳性克隆X931;
实施例2、采用HiTrap FF亲和层析柱,纯化培养细胞上清中的人白细胞介素-17受体样蛋白与可溶性Fc受体融合蛋白,根据紫外分光光度计初步测定的蛋白浓度,制作洗脱曲线,纯化出融合蛋白。采用BCA法蛋白定量,结果表明:每100ml转染细胞培养上清中约含100-150μg的Fc-受体融合蛋白。具体做法是:
1、添加100μl 1M Tris-HCl(pH9.0)收集液于1ml的收集管。装填HiTrapFF亲和层析柱。用至少5倍体积的去离子水或结合缓冲液洗柱;
2、采用5倍体积的流出缓冲液再生柱。采用5-10倍柱床体积的结合缓冲液平衡柱;
3、缓慢添加样品于亲和层析柱的中央,连接10ml的一次性注射器,打开流出阀,缓慢挤压使其流速约为1ml/min;
4、使用5-10倍柱床体积的结合缓冲液洗柱,直到流出液无蛋白为止;
5、采用2-5倍体积的流出缓冲液洗柱,小心收集最初的流出液。紫外分光光度计初步检测流出液的蛋白浓度;
6、填充5倍体积的20%的乙醇于层析柱,预防微生物的生长。密封层析柱的流出口。于4℃贮存;
7、采用BCA法(pierce)定量融合蛋白的浓度;
8、10%SDS-PAGE电泳,检测分离的融合蛋白的纯度。
实施例3、采用RT-PCR方法对细胞系X931分泌蛋白进行鉴定分别使用受体胞外区编码序列的正义引物:5’……ATAAAGCTTATGGAATCTCAACCTTTCCTG…..3’和人IgG1.Fc编码序列的反义引物:5’…AATTCTAGATCATTTACCCGGAGACAGGG…..3’,以野生型293T细胞为对照,采用RT-PCR方法对细胞系分泌蛋白进行鉴定,结果表明,细胞系X931含有Fc-受体融合蛋白的序列。
实施例4、采用Western blot对细胞系X931分泌蛋白进行鉴定
1、搜集X931细胞培养上清液,0.45um滤膜过滤;
2、将滤过的上清液经Hitrap HF亲和层析柱纯化,采用Millipore浓缩柱浓缩,-20℃或-80℃分装保存;
3、添加20μl上样缓冲液溶解500mg纯化的可溶性本发明融合蛋白上样,行10%SDS-PAGE;
4、于4℃冷室,100伏,300毫安转膜1.5小时;
5、于丽春红染液约5分钟染色,标记蛋白分子量Marker;
6、于封闭液(10%脱脂奶粉,TBST配制),37℃孵育封闭45分钟;
7、采用TBST室温洗膜三遍,持续摇动,每次15分钟;
8、按照1∶5000-10000比例TBST稀释抗IgG1.Fc特异性抗兔血清,在37℃,一抗孵育膜45分钟,持续摇动;
9、采用TBST室温洗膜三遍,持续摇动,每次15分钟;
10、按照1∶1000比例TBST稀释二抗,在37℃孵育膜45分钟,持续摇动。采用TBST室温洗膜三遍,持续摇动,每次15分钟;
11、按照1∶5000比例TBST稀释三抗,在37℃三抗孵育膜45分钟,持续摇动;
12、采用TBST室温洗膜三遍,持续摇动,每次15分钟;
13、将膜放在滤纸上简短晾干,与ECF底物孵育2-10分钟后,phosphoimager(520nm)显影。
结果表明,细胞系X931含有预期表达的Fc-受体融合蛋白的编码序列,能够稳定表达预期融合蛋白。
序列表
<160>2
<210>1
<211>1620
<212>DNA
<213>人工序列
<220>
<223>
<400>1
atggccccgt ggctgcagct ctgctccgtc ttctttacgg tcaacgcctg cctcaacggc 60
tcgcagctgg ctgtagccgc tggcgggtcc ggccgcgcgc ggggcgccga cacctgtggc 120
tggaggggag tggggccagc cagcagaaac agtgggctgt acaacatcac cttcaaatat 180
gacaattgta ccacctactt gaatccagtg gggaagcatg tgattgctga cgcccagaat 240
atcaccatca gccagtatgc ttgccatgac caagtggcag tcaccatcct ttggtcccca 300
ggggccctcg gcatcgaatt cctgaaagga tttcgggtaa tactggagga gctgaagtcg 360
gagggaagac agtgccaaca actgattcta aaggatccga agcagctcaa cagtagcttc 420
aaaagaactg gaatggaatc tcaacctttc ctgaatatga aatttgaaac ggattatttc 480
gtaaaggttg tcccttttcc ttccattaaa aacgaaagca attaccaccc tttcttcttt 540
agaacccgag cctgtgacct gttgttacag ccggacaatc tagcttgtaa acccttctgg 600
aagcctcgga acctgaacat cagccagcat ggctcggaca tgcaggtgtc cttcgaccac 660
gcaccgcaca acttcggctt ccgtttcttc tatcttcact acaagctcaa gcacgaagga 720
cctttcaagc gaaagacctg taagcagggg caaactacag agatgaccag ctgcctcctt 780
caaaatgttt ctccagggga ttatataatt gagctggtgg atgacactaa cacaacaaga 840
aaagtgatgc attatgcctt aaagccagtg cactccccgt gggccgggcc cgatatcgag 900
tccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga attcgagggt 960
gcaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggact 1020
cctgaggtca catgcgtggt ggtggacgta agccacgaag accctgaggt caagttcaac 1080
tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac 1140
aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc 1200
aaggagtaca agtgcaaggt ctccaacaaa gccctcccaa cccccatcga gaaaaccatc 1260
tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat 1320
gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tccaagcgac 1380
atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc 1440
gtgctggact ccgacggctc cttcttcctc tacagcaagc tcaccgtgga caagagcagg 1500
tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac 1560
acgcagaaga gcctctccct gtctccgggt aaatgactcg agcatgcatc tagagggccc 1620
<210>2
<211>531
<212>PRT
<213>人工序列
<220>
<223>
<400>序列号
Met Ala Pro Trp Leu Gln Leu Cys Ser Val Phe Phe Thr Val Asn
1 5 10 15
Ala Cys Leu Asn Gly Ser Gln Leu Ala Val Ala Ala Gly Gly Ser
20 25 30
Gly Arg Ala Arg Gly Ala Asp Thr Cys Gly Trp Arg Gly Val Gly
35 40 45
Pro Ala Ser Arg Asn Ser Gly Leu Tyr Asn Ile Thr Phe Lys Tyr
50 55 60
Asp Asn Cys Thr Thr Tyr Leu Asn Pro Val Gly Lys His Val Ile
65 70 75
Ala Asp Ala Gln Asn Ile Thr Ile Ser Gln Tyr Ala Cys His Asp
80 85 90
Gln Val Ala Val Thr Ile Leu Trp Ser Pro Gly Ala Leu Gly Ile
95 100 105
Glu Phe Leu Lys Gly Phe Arg Val Ile Leu Glu Glu Leu Lys Ser
110 115 120
Glu Gly Arg Gln Cys Gln Gln Leu Ile Leu Lys Asp Pro Lys Gln
125 130 135
Leu Asn Ser Ser Phe Lys Arg Thr Gly Met Glu Ser Gln Pro Phe
140 145 150
Leu Asn Met Lys Phe Glu Thr Asp Tyr Phe Val Lys Val Val Pro
155 160 165
Phe Pro Ser Ile Lys Asn Glu Ser Asn Tyr His Pro Phe Phe Phe
170 175 180
Arg Thr Arg Ala Cys Asp Leu Leu Leu Gln Pro Asp Asn Leu Ala
185 190 195
Cys Lys Pro Phe Trp Lys Pro Arg Asn Leu Asn Ile Ser Gln His
200 205 210
Gly Ser Asp Met Gln Val Ser Phe Asp His Ala Pro His Asn Phe
215 220 225
Gly Phe Arg Phe Phe Tyr Leu His Tyr Lys Leu Lys His Glu Gly
230 235 240
Pro Phe Lys Arg Lys Thr Cys Lys Gln Gly Gln Thr Thr Glu Met
245 250 255
Thr Ser Cys Leu Leu Gln Asn Val Ser Pro Gly Asp Tyr Ile Ile
260 265 270
Glu Leu Val Asp Asp Thr Asn Thr Thr Arg Lys Val Met His Tyr
275 280 285
Ala Leu Lys Pro Val His Ser Pro Trp Ala Gly Pro Asp Ile Glu
290 295 300
Ser Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
305 310 315
Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys
320 325 330
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
335 340 345
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
350 355 360
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
365 370 375
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
380 385 390
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
395 400 405
Lys Val Ser Asn Lys Ala Leu Pro Thr Pro Ile Glu Lys Thr Ile
410 415 420
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
425 430 435
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
440 445 450
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
455 460 465
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
470 475 480
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
485 490 495
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
500 505 510
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
515 520 525
Ser Leu Ser Pro Gly Lys
530 531
Claims (5)
1、一种人白细胞介素-17受体样蛋白与可溶性Fc受体的融合蛋白,它具有序列表中序列2的氨基酸残基序列或将序列2的氨基酸残基序列经过一个或几个氨基酸残基的取代、缺失或添加且能够用来寻找IL-17RLM-L的潜在偶联配体的由序列2衍生的蛋白质。
2、根据权利要求1所述的融合蛋白,其特征在于:所述蛋白质具有序列表中序列2的氨基酸残基序列。
3、编码权利要求1所述融合蛋白的DNA序列。
4、根据权利要求3所述的DNA序列,其特征在于:所述人白细胞介素-17受体样蛋白的编码基因是序列表中序列1的DNA序列。
5、可溶性人白细胞介素-17受体样分子稳定表达细胞系X-931 CGMCC №0755。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02123965 CN1216913C (zh) | 2002-07-10 | 2002-07-10 | 人白细胞介素-17受体样分子融合蛋白及其编码基因与表达细胞系 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02123965 CN1216913C (zh) | 2002-07-10 | 2002-07-10 | 人白细胞介素-17受体样分子融合蛋白及其编码基因与表达细胞系 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1467222A CN1467222A (zh) | 2004-01-14 |
CN1216913C true CN1216913C (zh) | 2005-08-31 |
Family
ID=34142572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02123965 Expired - Fee Related CN1216913C (zh) | 2002-07-10 | 2002-07-10 | 人白细胞介素-17受体样分子融合蛋白及其编码基因与表达细胞系 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1216913C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101115839B (zh) * | 2004-08-30 | 2011-05-04 | 杨梦甦 | 通过rh核心蛋白聚糖-Fc融合蛋白抑制纤维发生的方法 |
CN100391974C (zh) * | 2006-01-09 | 2008-06-04 | 浙江理工大学 | 一种重组胶原蛋白及其合成和表达纯化方法 |
CN102168074B (zh) * | 2011-02-17 | 2012-07-25 | 清华大学 | 一种重组腺病毒及其应用 |
CN102174475B (zh) * | 2011-02-17 | 2013-03-20 | 清华大学 | hIL-17RD-ECD单克隆抗体的制备及应用 |
CN102516397B (zh) * | 2011-12-26 | 2013-11-27 | 刘巍 | 一种白细胞介素-17受体阻断剂及其在制备抗心肌纤维化药物中的应用 |
CN106581643B (zh) * | 2016-12-07 | 2020-05-12 | 黄钟 | 白介素37作为药物在治疗骨关节炎和痛风中的应用 |
-
2002
- 2002-07-10 CN CN 02123965 patent/CN1216913C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1467222A (zh) | 2004-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102041412B1 (ko) | 면역글로불린 Fc 단편 유도체 | |
KR101567117B1 (ko) | 인터류킨-1 알파 항체 및 그의 사용 방법 | |
CN109776683B (zh) | 一种双特异性抗体及其制备方法与应用 | |
JP2021153593A (ja) | 制御性t細胞の増殖のためのインターロイキン−2変異タンパク質 | |
CN1753911A (zh) | 调节血管生成的α5β1整合素的嵌合的和人源化的抗体 | |
KR20210143237A (ko) | 항체-피롤로벤조디아제핀 유도체 컨쥬게이트 | |
CN1871259A (zh) | 具有改变的效应物功能的经改进的抗体和制备它的方法 | |
CN112851824A (zh) | 一种融合蛋白及其在制备新型冠状病毒亚单位疫苗中的应用 | |
KR20210091711A (ko) | 항 cdh6 항체-피롤로벤조디아제핀 유도체 컨쥬게이트 | |
CN1216913C (zh) | 人白细胞介素-17受体样分子融合蛋白及其编码基因与表达细胞系 | |
KR102450007B1 (ko) | IgM 영역을 이용한 융합단백질 플랫폼 | |
CN1919874A (zh) | 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途 | |
US8460673B2 (en) | Fusion protein inhibiting osteoclast formation, preparation method and medicine compositions thereof | |
CN106397569A (zh) | 一种治疗代谢疾病的突变细胞因子融合蛋白 | |
CN112823166A (zh) | 用于修饰的t细胞的条件活性嵌合抗原受体 | |
CN107759691B (zh) | 一种特异性结合axl的单克隆抗体 | |
CN111434681B (zh) | 抗h7n9全人源单克隆抗体6j15及其制备方法与应用 | |
CN111434684B (zh) | 抗h7n9全人源单克隆抗体5q2及其制备方法与应用 | |
CN111434685A (zh) | 抗h7n9全人源单克隆抗体9i17及其制法与应用 | |
CN113234165B (zh) | EpCAM的改造的结合蛋白及其应用 | |
CN108219005B (zh) | 一种白介素39特异性拮抗蛋白及其在治疗自身免疫性疾病中的应用 | |
CN100515496C (zh) | 免疫调节剂及其应用 | |
CN106832002A (zh) | 一种靶向pd‑1的融合蛋白及其相关应用 | |
CN109836494A (zh) | 一种靶向cd20的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 | |
CN114349850A (zh) | 抗体及其制备方法和编码核酸以及工程细胞 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |